Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-26. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
O-linked glycopeptides recently have been shown to exhibit excellent CNS permeability and efficacy in multiple animal models with disease states. In addition one of the most intriguing aspects thereof is the capability of O-glycosylation to extend half life, decrease clearance, and improve PK/PD thereof the active peptide beyond increasing CNS penetration. The innate utilization of sugars as solubilizing moieties in Phase II and III metabolism (glucuronic acids) has remarkably allowed an evolutionary advantage in that mammalian enzymes are not directly evolved to degrade O glycosylated products on larger moieties. The peculiar nature of O-linked glycopeptides is that there are numerous examples which are CNS penetrant. The fundamental basis of this effect is thought to involve "membrane hopping" or "hop diffusion". The non-brownian motion driven "hop diffusion" process is thought to occur due to discontinuity of the plasma membrane. "Hop diffusion" notably combines free diffusion and intercomparmental transitions. Recent examples notably include high permeability of met-enkephalin analogs amongst other peptides. The full mOR agonist pentapeptide DAMGO is also CNS penetrant upon introduction of glycosylation.
There has been a growing interest in the application of ion chromatography in the analysis of pharmaceutical drugs. Ion chromatography is used in different aspects of product development and quality control testing. For example, ion chromatography is used to improve stabilities and solubility properties of pharmaceutical active drugs molecules as well as used to detect systems that have higher tolerance for organic solvents. Ion chromatography has been used for the determination of analytes as a part of a dissolution test. For instance, calcium dissolution tests have shown that other ions present in the medium can be well resolved among themselves and also from the calcium ion. Therefore, ion chromatography has been employed in drugs in the form of tablets and capsules in order to determine the amount of drug dissolve with time. Ion chromatography is also widely used for detection and quantification of excipients or inactive ingredients used in pharmaceutical formulations. Detection of sugar and sugar alcohol in such formulations through ion chromatography has been done due to these polar groups getting resolved in ion column. Ion chromatography methodology also established in analysis of impurities in drug substances and products. Impurities or any components that are not part of the drug chemical entity are evaluated and they give insights about the maximum and minimum amounts of drug that should be administered in a patient per day.
Studies of twin adults indicate a 0.36 to 0.48 genetic influence on the likelihood of developing migraine. However, few studies examine non-European populations or distinguish between migraine with aura and migraine without aura. It is clear from family and population studies that migraine is a complex disorder, where numerous genetic risk variants exist, and where each variant increases the risk of migraine marginally. It is also known that having several of these risk variants increases the risk by a small to moderate amount. Single gene disorders that result in migraine are rare. One of these is known as familial hemiplegic migraine, a type of migraine with aura, which is inherited in an autosomal dominant fashion. Three main genes are involved in familial hemiplegic migraine via ion transport: CACNA1A, ATP1A2, and SCN1A. Another genetic disorder that has been associated with migraine is CADASIL syndrome (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). Despite some similarities in symptoms, ICHD-3 recommends using the diagnosis "headache attributed to CADASIL" (code 6.8.1) rather than migraine with aura (MA) or migraine without aura (MO) (codes 1.1 and 1.2). The TRPM8 gene, which codes for a cation channel, has been linked to migraine. One meta-analysis found a protective effect from angiotensin converting enzyme polymorphisms on migraine. The common forms of migraine are polygenetic, where common variants of numerous genes contribute to the predisposition for migraine.
Vascular spasm: Vasoconstriction is produced by vascular smooth muscle cells, and is the blood vessel's first response to injury. The smooth muscle cells are controlled by vascular endothelium, which releases intravascular signals to control the contracting properties. When a blood vessel is damaged, there is an immediate reflex, initiated by local sympathetic pain receptors, which helps promote vasoconstriction. The damaged vessels will constrict (vasoconstrict) which reduces the amount of blood flow through the area and limits the amount of blood loss. Collagen is exposed at the site of injury, the collagen promotes platelets to adhere to the injury site. Platelets release cytoplasmic granules which contain serotonin, ADP and thromboxane A2, all of which increase the effect of vasoconstriction. The spasm response becomes more effective as the amount of damage is increased. Vascular spasm is much more effective in smaller blood vessels. Platelet plug formation: Bone-marrow cells can be mobilized into the circulation during which myeloid-and megakaryocyte-biased progenitors and mature megakaryocytes may enter the bloodstream. Platelets derived from these megakaryocytes contribute broadly to hemostasis, thrombosis, inflammation, and vascular biology through platelet generation. Platelets adhere to damaged endothelium to form a platelet plug (primary hemostasis) and then degranulate. This process is regulated through thromboregulation. Plug formation is activated by a glycoprotein called von Willebrand factor (vWF), which is found in plasma.
Sources: en.wikipedia.org
Two or more of these techniques are often combined. This can improve preservation and reduce unwanted side effects such as the denaturation of nutrients by severe heat treatments. Common combinations are salting/drying, salting/marinating, salting/smoking, drying/smoking, pasteurization/refrigeration and controlled atmosphere/refrigeration. Other process combinations are currently being developed along the multiple hurdle theory.
Metabolism of glucose produces ATP, which increases the ATP to ADP ratio. The KATP channels close when the ATP to ADP ratio rises. The closure of the KATP channels causes the outward potassium ion current to diminish, leading to inward currents of potassium ions dominating. As a result, the potential difference across the membrane becomes more positive (as potassium ions accumulate inside the cell). This change in potential difference opens the voltage-gated calcium channels, which allows calcium ions from outside the cell to move into the cell down their concentration gradient. When the calcium ions enter the cell, they cause vesicles containing insulin to move to, and fuse with, the cell surface membrane, releasing insulin by exocytosis into the pancreatic capillaries. The venous blood then eventually empties into the hepatic portal vein. In addition to the triggering pathway, the amplifying pathway can cause increased insulin secretion without a further increase in intracellular calcium levels. The amplifying pathway is modulated by byproducts of glucose metabolism along with various intracellular signaling pathways; incretin hormone signaling being one important example.
==== Optic neuropathy ==== Some patients with copper deficiency have shown signs of vision and color loss. The vision is usually lost in the peripheral views of the eye. The bilateral vision loss is usually very gradual. An optical coherence tomography (OCT) shows some nerve fiber layer loss in most patients, suggesting the vision loss and color vision loss was secondary to optic neuropathy or neurodegeneration.
==== Rivaroxaban ==== Rivaroxaban chemically belongs to the group of n-aryloxazolidinones. Other drugs of that group are linezolid and tedizolid, both of whom are antibiotics. A synthesis of n-aryloxazolidinones starting with an O-silyl protected ethyl(2,3-dihydroxypropyl)-carbamate was published in 2016. In a one-pot reaction the carbamate cyclisizes to a 2-oxazolidone ring under slightly basic conditions while simultaneously the oxazolidone nitrogen is arylized by copper-catalization. For rivaroxaban in particular, 3-morpholinone substitutes the iodine in p-position of the benzene ring by copper-catalization. Afterwards, the silyl protecting group is removed and the resulting alcohol is replaced by an amino group which is then acylated in the last step. An industrial preparation of rivaroxaban was registered as a patent by Bayer Healthcare in 2005. It starts from N-(4-aminophenol)-morpholinone which is alkylated by a propylene oxide derivate that also contains a primary amine involved in a phthalimide protection group. Next, a phosgene equivalent is added to form the 2-oxazolidone ring and the phthalimide is removed. The free amine can now be acylated which leads to rivaroxaban. However, according to the patent the synthesis has “various disadvantages in the reaction management which has particularly unfavourable effects for preparation“. The patent also explains another synthesis starting from a chlorothiophene derivate that would be more suitable for the industrial process but points out that toxic solvents or reagents have to be removed from the final product.
== High-molecular-weight DNA extraction method == In this method, plant nuclei are isolated by physically grinding tissues and reconstituting the intact nuclei in a unique Nuclear Isolation Buffer (NIB). The plastid DNAs are released from organelles and eliminated with an osmotic buffer by washing and centrifugation. The purified nuclei are then lysed and further cleaned by organic extraction, and the genomic DNA is precipitated with a high concentration of CTAB. The highly pure, high molecular weight gDNA is extracted from the nuclei, dissolved in a high pH buffer, allowing for stable long-term storage.
Sources: en.wikipedia.org
reaction barrier The energy deficit that must be overcome in order for a particular chemical reaction to proceed. In transition state theory, the reaction barrier is interpreted as the difference between the zero-point energy of the activated complex formed in the reaction and that of the initial reactants. See also activation energy.
The skeletal effects of parathyroid hormone depend upon the pattern of systemic exposure. Transient elevations in parathyroid hormone levels after subcutaneous injection of Preotact stimulates new bone formation on trabecular and cortical bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity.
results in a different mass. The net result is that C3 and S1H4 differ by 3.4 mDa. Even smaller differences are achievable by carefully matching isotopes. For example, C4 and S1H313C1 differ by 1.1 mDa. Such differences can be resolved by high resolution mass spectrometry, which reaches resolution >1 million, sufficient to resolve ~1 mDa difference at m/z ~ 1000. Note that the electron mass is 0.5 mDa. There are many techniques for high resolution MS, but the highest resolution is achieved by FTMS with high magnetic field. With increasing magnetic field strength, the resolution and spectral acquisition speed increases linearly, while mass accuracy and dynamic range increases quadratically. Consequently, the highest resolution is achieved by high field FTMS, up to 21 Tesla. It reaches resolution >2.7 million at m/z ~ 400, and mass measurement accuracy < 80 ppb. They are often employed in geochemical and petrochemical studies, since there is a lot of money in petroleum industry, and petroleum composition is highly complex. Another application is in isotopic analysis of large proteins. Two proteins differing by a single isotopic atom are separated by
Commercial airliners typically cruise at altitudes of 9–12 km (30,000–39,000 ft) which is in the lower reaches of the stratosphere in temperate latitudes. This optimizes fuel efficiency, mostly due to the low temperatures encountered near the tropopause and low air density, reducing parasitic drag on the airframe. Stated another way, it allows the airliner to fly faster while maintaining lift equal to the weight of the plane. (The fuel consumption depends on the drag, which is related to the lift by the lift-to-drag ratio.) It also allows the airplane to stay above the turbulent weather of the troposphere. The Concorde aircraft cruised at Mach 2 at about 60,000 ft (18 km), and the SR-71 cruised at Mach 3 at 85,000 ft (26 km), all within the stratosphere. Because the temperature in the tropopause and lower stratosphere is largely constant with increasing altitude, very little convection and its resultant turbulence occurs there. Most turbulence at this altitude is caused by variations in the jet stream and other local wind shears, although areas of significant convective activity (thunderstorms) in the troposphere below may produce turbulence as a result of convective overshoot. On October 24, 2014, Alan Eustace became the record holder for reaching the altitude record for a manned balloon at 135,890 ft (41,419 m). Eustace also broke the world records for vertical speed skydiving, reached with a peak velocity of 1,321 km/h (822 mph) and total freefall distance of 123,414 ft (37,617 m), lasting 4 minutes and 27 seconds.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.